Future therapies.
New and improved therapies are required for type 1 and type 2 diabetic patients to assist the return of glucose homeostasis to as near normal as possible. More intensive use of existing therapies is proving beneficial, while potential new agents are progressing in development. These include agents to improve and partially mimic insulin action, such as peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists, stimulants of intracellular insulin signalling intermediates, and inhibitors of substances that deactivate insulin receptor tyrosine kinase activity. Novel agents to enhance nutrient-stimulated insulin release and promote the replication and neogenesis of beta-cells are emerging, along with new agents to combat obesity and dyslipidaemia. Gene therapy approaches to replace defective or destroyed beta-cells are feasible future options for both type 1 and type 2 diabetes.[1]References
- Future therapies. Bailey, C.J., Day, C. Current medical research and opinion. (2002) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg